Eli Lilly Gains from Big Earnings, Bullish Inflows

LLY is one of the world’s most valuable healthcare companies, having created medicines for diabetes, oncology, immunology, neuroscience, and obesity, along with using advanced technologies and AI to make more treatments. The company’s third-quarter fiscal 2025 earnings report, LLY showed $59.4 billion in revenue, a net margin of 31%, earnings growth of 116.6% in a year, and it increased current year guidance to reflect strong demand.

It’s no wonder LLY shares are up 33% this year, and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock.

Big Money Back for Eli Lilly

Institutional volumes reveal plenty. In the last year, LLY has endured some choppiness. But it’s once again enjoying strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in LLY shares. They reflect our proprietary inflow signal, pushing the stock higher:

Plenty of health care names are under accumulation right now. But there’s a powerful fundamental story happening with Eli Lilly.

Eli Lilly Fundamental Analysis

Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, LLY has had strong sales and earnings growth:

• 3-year sales growth rate (+17.4%)
• 3-year EPS growth rate (+32.9%)

Source: FactSet

Also, EPS is estimated to ramp higher this year by +34.3%.

Now it makes sense why the stock has been generating Big Money interest. LLY has a track record of strong financial performance.

Marrying great fundamentals with MoneyFlows software has found some big winning stocks over the long term.

Eli Lilly has been a top-rated stock at MoneyFlows for years. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

In the last five years, LLY has drawn 23 outlier inflow signals and is up 387.5%. The blue bars below show when LLY was a top pick on the Outlier 20 report…it’s clearly a Big Money favorite:

Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Eli Lilly Price Prediction

The LLY action isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in LLY at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level and follow our free weekly MoneyFlows insights.